falsefalse

Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies - Episode 2

Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape

,

Current Time 0:00
Duration 2:33
Loaded: 0%
Stream Type LIVE
Remaining Time 2:33
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Clinical Perspectives on Biomarker Testing in mBC
Now Viewing
EP. 2: Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape
EP. 3: Selecting the Optimal CDK4/6 Regimen for First-Line Therapy
EP. 4: Clinical Considerations for CDK4/6 Inhibition Beyond Progression
EP. 5: Expert Insights: Managing Patients with PIK3CA Mutations
EP. 6: Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice
EP. 7: The Emerging Role of Triplet Therapy in mBC: Opportunities and Challenges
EP. 8: The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

Video content above is prompted by the following:

  • Dr. Conlin to Dr. O’Shaughnessy: How do you approach repeat testing, which biomarkers you perform repeat testing for, and at what intervals?
    • Have you encountered any barriers to longitudinal molecular biomarker testing and how have you overcome them?

Related Content:

x